CL2022000264A1 - Síntesis de un inhibidor de calicreína plasmática a escala de proceso - Google Patents

Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Info

Publication number
CL2022000264A1
CL2022000264A1 CL2022000264A CL2022000264A CL2022000264A1 CL 2022000264 A1 CL2022000264 A1 CL 2022000264A1 CL 2022000264 A CL2022000264 A CL 2022000264A CL 2022000264 A CL2022000264 A CL 2022000264A CL 2022000264 A1 CL2022000264 A1 CL 2022000264A1
Authority
CL
Chile
Prior art keywords
synthesis
plasma kallikrein
kallikrein inhibitor
scale plasma
scale
Prior art date
Application number
CL2022000264A
Other languages
English (en)
Spanish (es)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of CL2022000264A1 publication Critical patent/CL2022000264A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL2022000264A 2019-08-06 2022-02-01 Síntesis de un inhibidor de calicreína plasmática a escala de proceso CL2022000264A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06

Publications (1)

Publication Number Publication Date
CL2022000264A1 true CL2022000264A1 (es) 2022-10-21

Family

ID=74504082

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022000264A CL2022000264A1 (es) 2019-08-06 2022-02-01 Síntesis de un inhibidor de calicreína plasmática a escala de proceso
CL2023000942A CL2023000942A1 (es) 2019-08-06 2023-03-30 Síntesis de un inhibidor de calicreína plasmática a escala de proceso .

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000942A CL2023000942A1 (es) 2019-08-06 2023-03-30 Síntesis de un inhibidor de calicreína plasmática a escala de proceso .

Country Status (20)

Country Link
US (1) US20220289683A1 (ar)
EP (1) EP4010320A4 (ar)
JP (1) JP2022543419A (ar)
KR (1) KR20220044276A (ar)
CN (1) CN114206839A (ar)
AR (1) AR119617A1 (ar)
AU (1) AU2020324422A1 (ar)
BR (1) BR112022002060A2 (ar)
CA (1) CA3149176A1 (ar)
CL (2) CL2022000264A1 (ar)
CO (1) CO2022002392A2 (ar)
CR (1) CR20220092A (ar)
EC (1) ECSP22016209A (ar)
IL (1) IL290113A (ar)
JO (1) JOP20220021A1 (ar)
MX (1) MX2022001608A (ar)
PE (1) PE20221009A1 (ar)
TW (1) TW202120481A (ar)
UY (1) UY38826A (ar)
WO (1) WO2021026182A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3113772T3 (pl) 2014-03-07 2021-04-06 Biocryst Pharmaceuticals, Inc. Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
AU2002319814A1 (en) * 2001-08-13 2003-03-03 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
KR20160148046A (ko) * 2008-12-18 2016-12-23 바이엘 인텔렉쳐 프로퍼티 게엠베하 살해충제로서의 테트라졸 치환된 안트라닐산 아미드
PL3113772T3 (pl) * 2014-03-07 2021-04-06 Biocryst Pharmaceuticals, Inc. Pirazole podstawiane trifluorometylem jako inhibitory ludzkiej kalikreiny osoczowej

Also Published As

Publication number Publication date
TW202120481A (zh) 2021-06-01
CO2022002392A2 (es) 2022-04-08
WO2021026182A1 (en) 2021-02-11
CR20220092A (es) 2022-06-03
JOP20220021A1 (ar) 2023-01-30
EP4010320A1 (en) 2022-06-15
AR119617A1 (es) 2021-12-29
ECSP22016209A (es) 2022-06-30
CL2023000942A1 (es) 2023-11-24
CN114206839A (zh) 2022-03-18
JP2022543419A (ja) 2022-10-12
AU2020324422A1 (en) 2022-03-17
US20220289683A1 (en) 2022-09-15
KR20220044276A (ko) 2022-04-07
EP4010320A4 (en) 2023-08-16
PE20221009A1 (es) 2022-06-15
MX2022001608A (es) 2022-03-11
UY38826A (es) 2021-02-26
IL290113A (en) 2022-03-01
CA3149176A1 (en) 2021-02-11
BR112022002060A2 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
BR112019004161A2 (pt) novo promotor e uso do mesmo
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2020001861A2 (es) Inhibidores de ror gamma
CL2023000942A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso .
CL2023002667A1 (es) Síntesis de omecamtiv mecarbil.
CL2019003057A1 (es) Compuestos antitumorales.
PE20190376A1 (es) Combinaciones farmaceuticas para el tratamiento del cancer
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CL2023000605A1 (es) Desimetrización de diol mediante sustitución aromática nucleófila
UY37551A (es) Activador de nrf2
BR112018074330A2 (pt) processos para preparar oligômeros morfolino fosforodiamidato
CO2022000748A2 (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.
MX2021012286A (es) Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
AR121730A1 (es) Nuevo promotor y procedimiento para producir glutatión usando el mismo
CY1123076T1 (el) Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta